Associated Papers
Contribution of BARD1 gene to male breast cancer- report of a family with different types of cancer.
Sarmadi A et al.
Current Problems in Cancer, 2025
Germline BARD1 Mutation in High-Risk Chinese Breast and Ovarian Cancer Patients.
Kwong A et al.
Cancers, 2025
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Association of a CHEK2 somatic variant with tumor microenvironment calprotectin expression predicts platinum resistance in a small cohort of ovarian carcinoma.
de Amorim IFG et al.
Plos One, 2025
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
Villa M et al.
British Journal of Cancer, 2024
Structural dynamics of clinically-reported VUS in the BARD1 ARD-BRCT region to predict the molecular basis of alterations.
Barua SA et al.
Journal of Biomolecular Structure & Dynamics, 2024
Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients.
Sierra-Díaz DC et al.
Human Genomics, 2024
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Meijer TG et al.
Cancers, 2024
Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer.
Keskin Karakoyun H et al.
Frontiers in Genetics, 2023
BARD1 mystery: tumor suppressors are cancer susceptibility genes.
Hawsawi YM et al.
Bmc Cancer, 2022
Germline variant screening with targeted next generation sequencing in prostate cancer: phenotype-genotype correlation.
Çakır AY et al.
Turkish Journal of Medical Sciences, 2022
A synergetic effect of BARD1 mutations on tumorigenesis.
Li W et al.
Nature Communications, 2021
BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
Śniadecki M et al.
Genes, 2020
p50 mono-ubiquitination and interaction with BARD1 regulates cell cycle progression and maintains genome stability.
Wu L et al.
Nature Communications, 2020
Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer.
Velázquez C et al.
Cancers, 2020
Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Alenezi WM et al.
Genes, 2020
The Effects of Genetic and Epigenetic Alterations of BARD1 on the Development of Non-Breast and Non-Gynecological Cancers.
Watters AK et al.
Genes, 2020
Transcriptomic and Genomic Testing to Guide Individualized Treatment in Chemoresistant Gastric Cancer Case.
Moisseev A et al.
Biomedicines, 2020
Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S et al.
Bmc Medical Genomics, 2020
REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification.
Tian Y et al.
Scientific Reports, 2019
Functional analysis of clinical BARD1 germline variants.
Toh MR et al.
Cold Spring Harbor Molecular Case Studies, 2019
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms.
Lima ZS et al.
Journal of Hematology & Oncology, 2019
Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB et al.
Bmc Cancer, 2019
An enhanced workflow for variant interpretation in UniProtKB/Swiss-Prot improves consistency and reuse in ClinVar.
Famiglietti ML et al.
Database : the Journal of Biological Databases and Curation, 2019
XPAT: a toolkit to conduct cross-platform association studies with heterogeneous sequencing datasets.
Yu Y et al.
Nucleic Acids Research, 2018
Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.
Jara L et al.
Biological Research, 2017
Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
DeLeonardis K et al.
The Breast Journal, 2017
BARD1 Gene Polymorphisms Confer Nephroblastoma Susceptibility.
Fu W et al.
Ebiomedicine, 2017
A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.
Castellanos E et al.
Scientific Reports, 2017
BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.
Marzec KA et al.
Cancer Letters, 2016
Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
De Brakeleer S et al.
Clinical Genetics, 2016
New concepts on BARD1: Regulator of BRCA pathways and beyond.
Irminger-Finger I et al.
The International Journal of Biochemistry & Cell Biology, 2016
The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population.
Zhang R et al.
International Journal of Medical Sciences, 2016
Genomic Biomarkers for Breast Cancer Risk.
Walsh MF et al.
Advances in Experimental Medicine and Biology, 2016
Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks.
Lee C et al.
Human Mutation, 2015
Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.
Ratajska M et al.
Oncology Reports, 2015
Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
Loke J et al.
Human Molecular Genetics, 2015
Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
Klonowska K et al.
Scientific Reports, 2015
The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.
Tang X et al.
Nucleic Acids Research, 2014
A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population.
Jupe ER et al.
Bba Clinical, 2014
The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience.
Mauer CB et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2014
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.
Tenedini E et al.
Leukemia, 2014
Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.
Tavtigian SV et al.
Biomarkers in Medicine, 2014
The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.
Gonzalez-Hormazabal P et al.
Molecular Biology Reports, 2012
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E et al.
Journal of Medical Genetics, 2012